Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. more
Time Frame | RANI | Sector | S&P500 |
---|---|---|---|
1-Week Return | -10.69% | -0.94% | -2.6% |
1-Month Return | -31.73% | -5.08% | -1.08% |
3-Month Return | -34.86% | -10.62% | 3.45% |
6-Month Return | -65.45% | -6.18% | 8.57% |
1-Year Return | -56.97% | 1.98% | 24.3% |
3-Year Return | -92.37% | -0.93% | 25.58% |
5-Year Return | -87.09% | 33.84% | 84.07% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 979.00K | 462.00K | 2.72M | - | - | [{"date":"2019-12-31","value":36.03,"profit":true},{"date":"2020-12-31","value":17,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | - | 1.31M | 822.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":62.65,"profit":true}] |
Gross Profit | 979.00K | 462.00K | 2.72M | (1.31M) | (822.00K) | [{"date":"2019-12-31","value":36.03,"profit":true},{"date":"2020-12-31","value":17,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-48.29,"profit":false},{"date":"2023-12-31","value":-30.25,"profit":false}] |
Gross Margin | 100.00% | 100.00% | 100.00% | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 28.04M | 17.01M | 54.32M | 63.45M | 66.10M | [{"date":"2019-12-31","value":42.43,"profit":true},{"date":"2020-12-31","value":25.73,"profit":true},{"date":"2021-12-31","value":82.17,"profit":true},{"date":"2022-12-31","value":95.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (27.07M) | (16.54M) | (51.60M) | (63.45M) | (66.10M) | [{"date":"2019-12-31","value":-2706500000,"profit":false},{"date":"2020-12-31","value":-1654400000,"profit":false},{"date":"2021-12-31","value":-5159900000,"profit":false},{"date":"2022-12-31","value":-6345100000,"profit":false},{"date":"2023-12-31","value":-6609900000,"profit":false}] |
Total Non-Operating Income/Expense | 891.00K | (185.00K) | (1.82M) | 354.00K | (2.85M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-20.76,"profit":false},{"date":"2021-12-31","value":-204.83,"profit":false},{"date":"2022-12-31","value":39.73,"profit":true},{"date":"2023-12-31","value":-319.64,"profit":false}] |
Pre-Tax Income | (26.59M) | (16.67M) | (53.05M) | (63.27M) | (67.88M) | [{"date":"2019-12-31","value":-2658700000,"profit":false},{"date":"2020-12-31","value":-1666800000,"profit":false},{"date":"2021-12-31","value":-5304700000,"profit":false},{"date":"2022-12-31","value":-6327400000,"profit":false},{"date":"2023-12-31","value":-6788300000,"profit":false}] |
Income Taxes | 10.00K | 35.00K | 41.00K | 70.00K | (33.91M) | [{"date":"2019-12-31","value":14.29,"profit":true},{"date":"2020-12-31","value":50,"profit":true},{"date":"2021-12-31","value":58.57,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-48447.14,"profit":false}] |
Income After Taxes | (26.60M) | (16.70M) | (53.09M) | (63.34M) | (33.97M) | [{"date":"2019-12-31","value":-2659700000,"profit":false},{"date":"2020-12-31","value":-1670300000,"profit":false},{"date":"2021-12-31","value":-5308800000,"profit":false},{"date":"2022-12-31","value":-6334400000,"profit":false},{"date":"2023-12-31","value":-3397000000,"profit":false}] |
Income From Continuous Operations | (26.59M) | (16.70M) | (53.09M) | (63.34M) | (71.17M) | [{"date":"2019-12-31","value":-2658700000,"profit":false},{"date":"2020-12-31","value":-1670300000,"profit":false},{"date":"2021-12-31","value":-5308800000,"profit":false},{"date":"2022-12-31","value":-6334400000,"profit":false},{"date":"2023-12-31","value":-7117000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (26.60M) | (16.70M) | (53.09M) | (63.34M) | (33.97M) | [{"date":"2019-12-31","value":-2659700000,"profit":false},{"date":"2020-12-31","value":-1670300000,"profit":false},{"date":"2021-12-31","value":-5308800000,"profit":false},{"date":"2022-12-31","value":-6334400000,"profit":false},{"date":"2023-12-31","value":-3397000000,"profit":false}] |
EPS (Diluted) | (0.11) | (0.12) | (0.63) | (1.28) | (1.33) | [{"date":"2019-12-31","value":-11.41,"profit":false},{"date":"2020-12-31","value":-11.94,"profit":false},{"date":"2021-12-31","value":-62.5,"profit":false},{"date":"2022-12-31","value":-128,"profit":false},{"date":"2023-12-31","value":-133,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RANI | |
---|---|
Cash Ratio | 1.50 |
Current Ratio | 1.60 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RANI | |
---|---|
ROA (LTM) | -56.83% |
ROE (LTM) | -225.35% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RANI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.87 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.07 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RANI | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 313.17 |
P/B | 15.05 |
Price/FCF | NM |
EV/R | 84.28 |
EV/Ebitda | NM |
Rani Therapeutics Holdings Inc (RANI) share price today is $1.42
Yes, Indians can buy shares of Rani Therapeutics Holdings Inc (RANI) on Vested. To buy Rani Therapeutics Holdings Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RANI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Rani Therapeutics Holdings Inc (RANI) via the Vested app. You can start investing in Rani Therapeutics Holdings Inc (RANI) with a minimum investment of $1.
You can invest in shares of Rani Therapeutics Holdings Inc (RANI) via Vested in three simple steps:
The 52-week high price of Rani Therapeutics Holdings Inc (RANI) is $8.75. The 52-week low price of Rani Therapeutics Holdings Inc (RANI) is $1.3.
The price-to-earnings (P/E) ratio of Rani Therapeutics Holdings Inc (RANI) is
The price-to-book (P/B) ratio of Rani Therapeutics Holdings Inc (RANI) is 15.05
The dividend yield of Rani Therapeutics Holdings Inc (RANI) is 0.00%
The market capitalization of Rani Therapeutics Holdings Inc (RANI) is $81.97M
The stock symbol (or ticker) of Rani Therapeutics Holdings Inc is RANI